A Targeted Learning Framework for Estimating Restricted Mean Survival Time Difference using Pseudo-observations

📅 2026-01-09
📈 Citations: 0
Influential: 0
📄 PDF
🤖 AI Summary
This study addresses the challenge of efficiently and robustly estimating the difference in restricted mean survival time (RMST) under right-censored time-to-event data commonly encountered in clinical trials. The authors propose a novel framework that integrates targeted minimum loss-based estimation (TMLE) with pseudo-observations, marking the first application of this combination for RMST difference estimation. Additionally, they introduce an innovative replication reference approach to facilitate sensitivity analysis under right censoring. Empirical evaluation on real clinical trial data demonstrates that the proposed method substantially improves estimation efficiency while maintaining robustness, offering a theoretically sound and practically valuable tool for RMST-based comparative analyses in survival settings.

Technology Category

Application Category

📝 Abstract
A targeted learning (TL) framework is developed to estimate the difference in the restricted mean survival time (RMST) for a clinical trial with time-to-event outcomes. The approach starts by defining the target estimand as the RMST difference between investigational and control treatments. Next, an efficient estimation method is introduced: a targeted minimum loss estimator (TMLE) utilizing pseudo-observations. Moreover, a version of the copy reference (CR) approach is developed to perform a sensitivity analysis for right-censoring. The proposed TL framework is demonstrated using a real data application.
Problem

Research questions and friction points this paper is trying to address.

restricted mean survival time
time-to-event outcomes
clinical trial
RMST difference
right-censoring
Innovation

Methods, ideas, or system contributions that make the work stand out.

targeted learning
restricted mean survival time
pseudo-observations
TMLE
sensitivity analysis
🔎 Similar Papers
No similar papers found.
M
Man Jin
Data and Statistical Sciences, AbbVie Inc.
Yixin Fang
Yixin Fang
AbbVie
machine learningreal-world dataclinical trials